|
|
(9 intermediate revisions not shown) |
Line 121: |
Line 121: |
| <div style="text-align: left;"> | | <div style="text-align: left;"> |
| <p class="MsoNormal" style="text-align: justify;"><b | | <p class="MsoNormal" style="text-align: justify;"><b |
- | style=""><u>Introduction<o:p></o:p></u></b></p> | + | style=""><u>Introduction<o:p></o:p></u></b> |
- | <p class="MsoNormal" style="text-align: justify;"><o:p> </o:p></p> | + | <p class="MsoNormal" style="text-align: justify;"><o:p> </o:p></p></div> |
- | <p class="MsoNormal" style="text-align: justify;"><span | + | <p style="text-align: justify;"><span |
| style="" lang="EN-GB">In order to create a universal | | style="" lang="EN-GB">In order to create a universal |
| restriction | | restriction |
- | enzyme we followed several ideas and models. The first and most | + | enzyme, we followed several ideas and models. The first and most |
| promising idea | | promising idea |
| we had was to create a monomeric restriction enzyme as it represents the optimal and | | we had was to create a monomeric restriction enzyme as it represents the optimal and |
Line 136: |
Line 136: |
| style="" lang="EN-GB">If we are able to employ a | | style="" lang="EN-GB">If we are able to employ a |
| monomeric enzyme, | | monomeric enzyme, |
- | this protein would have a couple of advantages. Most importantly we | + | this protein would have a couple of advantages: Most importantly we |
| would no longer | | would no longer |
| need two separate oligonucleotides to achieve specific binding and | | need two separate oligonucleotides to achieve specific binding and |
- | cutting of
| + | cleavage of |
- | the target DNA. Also only one protein has to be purified – | + | the target DNA. Also, only one protein has to be purified – |
| thus saving time and | | thus saving time and |
| money. A scientific advantage is the option to optimize the monomer by | | money. A scientific advantage is the option to optimize the monomer by |
Line 146: |
Line 146: |
| display. Using this technology, we would have the chance to create a | | display. Using this technology, we would have the chance to create a |
| thermostable, specific, universal restriction enzyme whose DNA binding | | thermostable, specific, universal restriction enzyme whose DNA binding |
- | activity
| + | specificity |
- | is only created by a single oligonucleotide.<o:p></o:p></span></p> | + | is simply created by a single oligonucleotide.<o:p></o:p></span></p> |
| <p class="MsoNormal" style="text-align: justify;"><u><span | | <p class="MsoNormal" style="text-align: justify;"><u><span |
| style="" lang="EN-GB"><o:p><span | | style="" lang="EN-GB"><o:p><span |
| style="text-decoration: none;"></span></o:p></span></u><span | | style="text-decoration: none;"></span></o:p></span></u><span |
- | style="" lang="EN-GB">Our goal was firstly to create | + | style="" lang="EN-GB">Our goal was first, to create |
- | a Fok-monomer which | + | a Fok-monomer that |
- | is able to cut DNA without a primary dimerization step and secondly to | + | is able to cut DNA without a primary dimerization step, and second, to |
| show | | show |
| that our heterodimeric interface design works properly. To reach this, | | that our heterodimeric interface design works properly. To reach this, |
Line 162: |
Line 162: |
| </o:p></span></p> | | </o:p></span></p> |
| <p class="MsoNormal" style="text-align: justify;"><span | | <p class="MsoNormal" style="text-align: justify;"><span |
- | style="" lang="EN-GB"><o:p><br /> | + | style="" lang="EN-GB"><o:p></b><br /> |
| </o:p></span><b style=""><u><span | | </o:p></span><b style=""><u><span |
| style="" lang="EN-GB">Results<o:p></o:p></span></u></b></p> | | style="" lang="EN-GB">Results<o:p></o:p></span></u></b></p> |
| <p class="MsoNormal" style="text-align: justify;"><u><span | | <p class="MsoNormal" style="text-align: justify;"><u><span |
- | style="" lang="EN-GB">3D modelling and design goals<o:p></o:p></span></u></p> | + | style="" lang="EN-GB">3D modeling and design goals<o:p></o:p></span></u></p></b> |
| <p class="MsoNormal" style="text-align: justify;"></p> | | <p class="MsoNormal" style="text-align: justify;"></p> |
| <table style="text-align: left; width: 208px; height: 225px;" | | <table style="text-align: left; width: 208px; height: 225px;" |
Line 177: |
Line 177: |
| </tr> | | </tr> |
| <tr> | | <tr> |
- | <td><span style="font-size: 10pt;" lang="EN-GB">Fig1.: | + | <td><span style="font-size: 10pt;" lang="EN-GB">Fig. 1: |
- | <st1:place w:st="on"><st2:Sn w:st="on">Scheme</st2:Sn> | + | <st1:place w:st="on"><st2:Sn w:st="on">Scheme of monomoeric Fok:</st2:Sn> |
| <st2:Sn w:st="on">I.</st2:Sn></st1:place> | | <st2:Sn w:st="on">I.</st2:Sn></st1:place> |
- | lipocalin<span style=""> </span>II. | + | lipocalin,<span style=""> </span>II. |
- | Foka/i (heterodimers) III. | + | Foka/Foki (heterodimers), III. |
- | Linker<span style=""> </span>IV. His-Tag</span></td> | + | Linker,<span style=""> </span>IV. His-Tag</span></td> |
| </tr> | | </tr> |
| </tbody> | | </tbody> |
Line 190: |
Line 190: |
| style="font-size: 10pt;" lang="EN-GB"></span><span | | style="font-size: 10pt;" lang="EN-GB"></span><span |
| style="" lang="EN-US">The necessary parts in the | | style="" lang="EN-US">The necessary parts in the |
- | model of an | + | model of a |
- | monomeric restriction encyme are: Tag-binding protein - Fok | + | monomeric restriction enzyme are: Tag-binding protein (lipocalin) - Fok |
| heterodimer1 - | | heterodimer1 - |
- | linker - Fok herterodimer2 (Fig1). <o:p></o:p></span></p> | + | linker - Fok heterodimer2 (Fig. 1). <o:p></o:p></span></p> |
| <p class="MsoNormal" style="text-align: justify;"><span | | <p class="MsoNormal" style="text-align: justify;"><span |
| style="font-size: 10pt;" lang="EN-US"><o:p> </o:p></span><span | | style="font-size: 10pt;" lang="EN-US"><o:p> </o:p></span><span |
Line 229: |
Line 229: |
| </o:p></span><span style="font-size: 10pt;" | | </o:p></span><span style="font-size: 10pt;" |
| lang="EN-US"><o:p></o:p></span><span | | lang="EN-US"><o:p></o:p></span><span |
- | style="font-size: 9pt;" lang="EN-US">Tab.:1 list of | + | style="font-size: 9pt;" lang="EN-US">Tab. 1: List of |
| parts usable for | | parts usable for |
| Fok Monomer<o:p></o:p></span></p> | | Fok Monomer<o:p></o:p></span></p> |
Line 235: |
Line 235: |
| style="font-size: 9pt;" lang="EN-US"><o:p></o:p></span><span | | style="font-size: 9pt;" lang="EN-US"><o:p></o:p></span><span |
| style="" lang="EN-US">In order to purify this fusion | | style="" lang="EN-US">In order to purify this fusion |
- | protein we had | + | protein, we employed an N-terminal tag. The binding protein (a lipocalin-derived binding protein referred to as anticalin in analogy to antibodies) mediates |
- | to employ a N-terminal tag. The binding protein (a lipocalin) mediates
| + | |
| between the | | between the |
- | FokI protein and the tagged oligo</span><span style="" | + | FokI protein and the tagged oligonucleotide</span><span style="" |
| lang="EN-GB">. Both parts of the Fok heterodimers are | | lang="EN-GB">. Both parts of the Fok heterodimers are |
- | associated with a long linker allowing | + | associated with a long flexible linker allowing |
| them to establish the cutting site conformation. This artificial | | them to establish the cutting site conformation. This artificial |
| restriction | | restriction |
Line 248: |
Line 247: |
| <p class="MsoNormal" style="text-align: justify;"><span | | <p class="MsoNormal" style="text-align: justify;"><span |
| style="" lang="EN-GB"><o:p></o:p>Before | | style="" lang="EN-GB"><o:p></o:p>Before |
- | we started in the wet lab we planned all | + | we started in the wet lab, we thoroughly planned all |
- | the individual steps and to figure out the best way to create the Fok | + | the individual steps. To figure out the best way to create the Fok |
- | monomer, | + | monomer, we first designed it <i style="">in |
- | so the first thing we did was to design a Fok monomer <i style="">in
| + | |
| silico.<o:p></o:p></i></span></p> | | silico.<o:p></o:p></i></span></p> |
| <p class="MsoNormal" style="text-align: justify;"><span | | <p class="MsoNormal" style="text-align: justify;"><span |
Line 266: |
Line 264: |
| </tr> | | </tr> |
| <tr> | | <tr> |
- | <td><span style="font-size: 10pt;" lang="EN-GB">Fig2.: | + | <td><span style="font-size: 10pt;" lang="EN-GB">Fig. 2: |
| 3D model of Fok Monomer</span></td> | | 3D model of Fok Monomer</span></td> |
| </tr> | | </tr> |
Line 272: |
Line 270: |
| </table> | | </table> |
| <p class="MsoNormal" style="text-align: justify;"><span | | <p class="MsoNormal" style="text-align: justify;"><span |
- | style="" lang="EN-GB">The model (Fig2.) shows that we | + | style="" lang="EN-GB">The model (Fig. 2) shows that we |
| have to use a | | have to use a |
- | linker which is something about 70 Angström in length to | + | linker which is about 70 Angstrom in length to |
- | provide the required
| + | span the required |
- | distance between the two Fok parts. Therefore we decided to order two | + | distance between the two Fok parts. Therefore, we decided to order two |
- | complement oligonucleotides encoding one 36 amino acid glycine-serine
| + | complementary oligonucleotides encoding a 36 amino acid long glycine-serine |
| linker.<o:p></o:p></span></p> | | linker.<o:p></o:p></span></p> |
| <p class="MsoNormal" style="text-align: justify;"><span | | <p class="MsoNormal" style="text-align: justify;"><span |
Line 292: |
Line 290: |
| style="text-decoration: underline;">Cloning</span></span></p> | | style="text-decoration: underline;">Cloning</span></span></p> |
| <p class="MsoNormal" style="text-align: justify;"><span | | <p class="MsoNormal" style="text-align: justify;"><span |
- | style="" lang="EN-GB">However at this stage the first | + | style="" lang="EN-GB">However, at this stage the first |
| problem | | problem |
- | appeared.<o:p></o:p> This are the oligonucleotides, each | + | appeared.<o:p></o:p> These are the oligonucleotides, each |
- | 120aa long
| + | 120 nt long, which we ordered from Mr.Gene. Unfortunately, we made a mistake when |
- | that we ordered from Mr.Gene. Unfortunately we made a mistake when
| + | |
| ordering the | | ordering the |
- | complement oligonucleotide. As you can see we have two mismatches
| + | complementary oligonucleotide. Accidentally we introduced two mismatches |
| (compare | | (compare |
- | coloured bases in the sequence). But somehow we managed to dimerize the
| + | colored bases in the sequence). But somehow we managed to dimerize the |
| two | | two |
- | oligos.<o:p></o:p> After dimerization in the thermo cycler
| + | oligonucleotides.<o:p></o:p> After dimerization in the thermocycler |
| and | | and |
| cloning into a pMA (BBa_K243031) vector (XbaI/AgeI) some mutations | | cloning into a pMA (BBa_K243031) vector (XbaI/AgeI) some mutations |
| appeared in | | appeared in |
- | the 36GSLinker gene caused by the mismatches. But since there was no | + | the 36GSLinker gene caused by the mismatches. As there was no |
| frame | | frame |
| shift we decided to carry on. <o:p></o:p><br /> | | shift we decided to carry on. <o:p></o:p><br /> |
- | Firstly we picked the parts we were going to
| + | First, we picked the parts we were going to |
| use. We decided to use one we already completed in our earlier | | use. We decided to use one we already completed in our earlier |
- | experiments. His | + | experiments: His |
| – FluA – <st1:place w:st="on"><st1:City | | – FluA – <st1:place w:st="on"><st1:City |
| w:st="on">Split</st1:City></st1:place> - | | w:st="on">Split</st1:City></st1:place> - |
- | Foki (BBa_K243010) has all the functions we needed. These are (I) a tag | + | Foki (BBa_K243010) had all the functions we needed. These are (i) a purification tag, |
- | to
| + | (ii) a Fok domain and (iii) the anticalin that binds the |
- | purify, (II) a Fok domain and (III) the anticalin which binds the
| + | tagged |
- | modified
| + | oligonucleotide (Fig. 1). Cloning the linker (no part) behind these parts was |
- | oligonucleotide Fig.1. Cloning the linker (no part) behind those was | + | |
| the next | | the next |
- | step. We followed the assembly standard 25 and cut the vector with AgeI | + | step. We followed the assembly standard 25 and opened the vector with AgeI |
| and | | and |
- | PstI and the inserted with NgoMIV and PstI.<o:p></o:p></span></p> | + | PstI and cut the inserted with NgoMIV and PstI.<o:p></o:p></span></p> |
| <p class="MsoNormal" style="text-align: justify;"><span | | <p class="MsoNormal" style="text-align: justify;"><span |
| style="" lang="EN-GB"><o:p> | | style="" lang="EN-GB"><o:p> |
Line 336: |
Line 332: |
| <td> | | <td> |
| <p class="MsoNormal"><span | | <p class="MsoNormal"><span |
- | style="font-size: 10pt;" lang="EN-GB">Fig3. gele | + | style="font-size: 10pt;" lang="EN-GB">Fig. 3: Gel |
| picture of test digest<o:p></o:p></span></p> | | picture of test digest<o:p></o:p></span></p> |
| </td> | | </td> |
Line 344: |
Line 340: |
| </o:p><br /> | | </o:p><br /> |
| However, we ran into some more problems. After cloning Foka | | However, we ran into some more problems. After cloning Foka |
- | (BBa_K243000) behind this construct, again assembly standard 25, we | + | (BBa_K243000) after the other parts, again assembly standard 25, we |
- | performed | + | performed test restriction digests cutting out the insert to confirm its size. These digests showed that the |
- | some test digestions to cut out the insert again. These showed that the
| + | |
| plasmid | | plasmid |
- | became even smaller as it would be without an insertion (pEX: ~ 4,5kb | + | became even smaller as it would be without an insertion (pEX: ~ 4,5kbp |
| and after | | and after |
- | test digestion ~ 2,2kb). The Insert should be about 1,9kb but as you | + | test digestion ~ 2,2kbp). The insert should have a size of about 1.9 kbp but was found to be only about 900 bp (Fig. 3). <span style=""> </span>The sequencing did not work either.<o:p><br /> |
- | can see in
| + | |
- | Fig.3 it´s about 900k. <span style=""> </span>Also | + | |
- | the sequencing
| + | |
- | went wrong.<o:p><br />
| + | |
| </o:p></span></p> | | </o:p></span></p> |
| <p class="MsoNormal" style="text-align: justify;"><span | | <p class="MsoNormal" style="text-align: justify;"><span |
- | style="" lang="EN-GB">Most likely the active Fok did | + | style="" lang="EN-GB">Most likely, the active Fok did |
| cut the plasmid | | cut the plasmid |
- | and promoted deletion of the Fok gene, what gave mutated cells a | + | and promoted deletion of the Fok gene, which gave such mutated cells a |
| significant | | significant |
- | growth advantage. After that we decided to order the 36GS-linker (GSAT | + | growth advantage. After we encountered these problems, we decided to order the 36GS-linker (GSAT |
| Linker: | | Linker: |
| BBa_K243029) as gene synthesis.<o:p></o:p></span></p> | | BBa_K243029) as gene synthesis.<o:p></o:p></span></p> |
Line 369: |
Line 360: |
| <p class="MsoNormal" style="text-align: justify;"><span | | <p class="MsoNormal" style="text-align: justify;"><span |
| style="" lang="EN-GB"><o:p></o:p>This | | style="" lang="EN-GB"><o:p></o:p>This |
- | time the order was well planned but it | + | time the order was well planned but, unfortunately, it |
- | took over 4 weeks to get them. Unfortunately the genes arrived too | + | took over 4 weeks for the synthesis and delivery, and the genes arrived too |
| late. Once | | late. Once |
- | again we have to make all the cloning steps. As of mid October 2009 the | + | again we have to make all the cloning steps. As of mid October 2009, the |
| project | | project |
| is still in progress.<o:p></o:p></span></p> | | is still in progress.<o:p></o:p></span></p> |